Revolution- Study drug RMC-5127 for advanced KRAS G12V solid tumors (RMC-5127-001)

Study Details

Full Title

[RMC-5127-001] Phase 1/1b, Multicenter, Open-Label, Study of RMC-5127 in Patients with Advanced KRAS G12V-Mutant Solid Tumors

Principal Investigator

John
Strickler

Protocol Number

PRO00119569

NCT ID

NCT07349537

Phase

I

Enrollment Status

Open to Enrollment
ClinicalTrials.gov